Immunization of crossbred and F1 mice with combined killed and live Gross leukemia virus AKR type-C viral vaccines suppressed endogenous N-type AKR virus up to 10,000-fold for significant periods during early life. Since several previous studies in the same Assay of Virus in Tails of Mice Given Vaccine or Passive Antibodies. The tail virus assay procedure was essentially that described by Lilly et al. (9). Thirty to forty days after immunization of the F1 mice with MSV(GLV) (see next section) and at specified later periods 2 cm terminal segments of the tail were cut off each test and control mouse with a sharp scissors. Segments of tails were rinsed with ether and following evaporation they were ground with Alundum using chilled mortar and pestle and suspended in cold Eagle's basal medium containing 20% veal infusion broth. The extracts (approximately 2% by wt/vol) were lightly centrifuged and sonicated and tested for infectious murine leukemia virus by the XC cell method (18) using a continuous passage line of SC-1 wild mouse cells (19) or secondary NIH Swiss embryo cells. Titers were expressed as the number of plaque-forming units per 0.4 ml of 2% extract.
sions or of prevention of the spontaneous leukemias and other cancers attributable to these expressions. In this communication we report significant suppression of endogenous ecotropic type-C virogenes in tissues of mice immunized with a combination of killed and live vaccines.
The feasibility of attempts to modify or prevent spontaneous cancers in laboratory mice by suppressing endogenous virogene expression was suggested by previously demonstrated correlations of high and low titers of natural virus expressions early in life with correspondingly high and low tumor incidences later in life (6) (7) (8) (9) (10) . Reports of humoral and cell-mediated immune responses to endogenous type-C viruses in murine systems, suggesting that natural antibodies were factors in controlling endogenous type-C viral and cancer expressions (11) (12) (13) (14) (15) , provided the initial impetus to attempt active vaccine suppression of spontaneous expressions.
Also, in several experiments Whitmire and Huebner (16) and Whitmire (17) , using radiation leukemia virus as a live vaccine, achieved significant reduction in the incidence of subcutaneous sarcomas produced in C57BL/J mice by 3- methylcholanthrene.
MATERIALS AND METHODS
Mice. The vaccine studies were done in four crossbred mouse systems and in their F1 progeny. The AKR, C57L, and SWR mice were obtained from The Jackson Laboratory, Bar Harbor, Me.; NIH Swiss mice, from the National Institutes of Health; BALB/cCan, from the Frederick Cancer Research Center (FCRC), Frederick, Md.
Assay of Virus in Tails of Mice Given Vaccine or Passive Antibodies. The tail virus assay procedure was essentially that described by Lilly et al. (9) . Thirty to forty days after immunization of the F1 mice with MSV(GLV) (see next section) and at specified later periods 2 cm terminal segments of the tail were cut off each test and control mouse with a sharp scissors. Segments of tails were rinsed with ether and following evaporation they were ground with Alundum using chilled mortar and pestle and suspended in cold Eagle's basal medium containing 20% veal infusion broth. The extracts (approximately 2% by wt/vol) were lightly centrifuged and sonicated and tested for infectious murine leukemia virus by the XC cell method (18) using a continuous passage line of SC-1 wild mouse cells (19) or secondary NIH Swiss embryo cells. Titers were expressed as the number of plaque-forming units per 0.4 ml of 2% extract.
Live MSV(GLV) Vaccines. MSV(GLV), a Gross leukemia virus (GLV) pseudotype murine sarcoma virus (MSV) maintained since 1967 in our laboratories by serial transmission in NIH Swiss mice, was produced in quantity by transmission to large numbers of newborn NIH Swiss mice. Ten percent (wt/vol) virus pools were made into lOX concentrated Moloney procedure concentrates (20) from subcutaneous sarcomas. High titered (103-104) sarcoma virus preparations were used as a live vaccine (see design of experiment below). The live virus vaccine was 100% lethal within 12 days when given at 10-1 dilution to unvaccinated F1 mice. However, when given at the same dilution as a live vaccine challenge to vaccinated C57L, NIH Swiss, SWR, and BALB/c pregnant mice at mid-term and to the crossbred F1 progeny at 10 days of age, the sarcoma virus had no tumorous effects. The live sarcoma virus challenge was intended not only to confirm protective immunity in the mother which was passed to the F1 offspring but to provide more persistent active typespecific immunity to the endogenous AKR-GLV type virus in the F1 progeny (Huebner and Lane, unpublished data Tables 1-5 were selected for our initial studies because we had previously obtained background information on their natural viral and tumor expressions not only in the F1 generation but subse- complete adjuvant was given with the first injection only. Sera were collected from all vaccinated and control females 14-28 days after the last injection of vaccine, which was approximately 42-56 days after the first injection of vaccine.
Step 2. The vaccinated females were bred to AKR males and in most instances challenged subcutaneously with live MSV(GLV) at maximum focus-forming titers (103-104) during early pregnancy; sarcomas were not observed.
Step 3. At 10 days of age all of the F1 offspring of vaccines were also challenged intramuscularly with the same dose of live MSV(GLV). Except for several small nodules that regressed, typical sarcomas were not observed in any of the vaccinated F1 mice; on the other hand all unvaccinated control F1 progeny from the N type control group females selected for MSV(GLV) challenge succumbed rapidly to growing sarcomas within 12 days.
Step 4. Tail specimens taken from F1 mice at 30-40 days of age were tested for infectious virus in the XC test (18) . Sera collected from all mother mice at approximately 30-40 days after last immunization were tested for neutralizing antibodies in the XC test.
For additional studies not reported herein F1 females from C57L, SWR, NIH Swiss, and BALB/c/AKR crosses were selected, immunized as in the first cross, and mated to. AKR males in order to provide backcross mice for further studies. Since the progeny of F1's backcrossed to AKR are known to develop cancers more rapidly and at higher incidences (8, 9) than do F1's, they can be expected to provide more rapid opportunities for evaluating the effects of vaccines on tumor incidence.
RESULTS AND DISCUSSION
Tail virus titers are shown in Tables 1-5 . The data clearly demonstrate that the vaccine procedures suppressed endogenous infectious virogene expressions by factors of 100 to 100,000 during the first 30-118 days of life in four different crossbred test systems. Although we cannot yet predict precisely the expected incidences of tumors in the vaccinated mice, background information on tumor incidences in controls is available. We feel that the prospects for reduction of spontaneous tumors in the vaccinated groups are good, since complement fixation tests for p30 antigen at 125 days of age 2. Evidence provided by Chattopadhyay and his associates (24) established the Akv-1 locus in the AKR mouse as the site of the structural sequences responsible for the fully expressed ecotropic AKR virus found in most of our F1 control mice. It is also clear in three of the crossbred systems that the ecotropic virogenes suppressed by the AKR-GLV vaccines had to be derived from the male AKR parent, since most of the maternal parents were known to have only xenotropic virus, a virus which is not infectious for murine cells (25) (26) (27) (28) (29) . Characterization of the viruses isolated from the F1 control mice of these three crosses revealed that they were immunologically indistinguishable from the ecotropic AKR virus in that they were completely neutralized by type-specific murine AKR and GLV antisera (R. Huebner, W. Lane, and R. Trimmer, unpublished data). that the completion and extension of these studies could possibly provide definitive evidence proving that endogenous virogenes and oncogenes are specific causes of spontaneous leukemia and other cancers in mice, and at the same time suggesting additional modes for protection against not only spontaneous cancer but possibly also cancer induced by environmental agents (16, 17) .
Similar vaccine approaches for prevention of spontaneous and induced cancers in other rodents such as hamsters and rats may also be feasible, since they also develop tumors attributable to endogenous type-C viruses (R. Huebner, A. Freeman, R. Gilden, and S. Rasheed, unpublished data). Should future studies establish that vaccine-induced or passive antibodies suppress primary gene expression as well as secondary replication, and this does not seem unlikely, attempts to modify other genetically determined disease by suppressing harmful aberrant genes with active or passive immunity may also prove to be feasible.
